Alexei Savinov, MD, PhD

Associate Scientist
Sanford Research
Pediatrics & Rare Diseases
(605) 312-6019

Dr. Savinov is an immunologist and cellular biologist with expertise in diabetes and autoimmune diseases. He came to Sanford Health from the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA where he served as a Staff Scientist. Previous to that he was a Research Associate at the Jackson Laboratory in Bar Harbor, ME. Prior to that he held a position as a Postdoctoral Fellow in the Department of Pharmacology and Experimental Therapeutics at the University of Maryland in Baltimore, He is currently a faculty member in the Diabetes Group at Sanford Research, where his lab is focused on studying the underlying mechanisms controlling organ-specific autoimmune diseases such as Type I Diabetes.

Areas of expertise:
Autoimmunity, type-1 diabetes, lymphocyte-endothelial interactions, proteolysis

Selected publications:
Amatya C, Radichev IA, Ellefson J, Williams M, and Savinov AY. (2017) Self-transducible Bimodal Pdx1-Foxp3 Protein Rescues Insulin Secretion and Curbs Autoimmunity Boosting Treg Cells in Type 1 Diabetic Mice. Molecular Therapy, in press.

Radichev IA, Maneva-Radicheva LV, Amatya C, Salehi M, Parker C, Ellefson J, Burn P, and Savinov AY. Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes. J Immunol. 2016 Feb 15;196(4):1495-506. doi: 10.4049/jimmunol.1403251.

Radichev IA, Maneva-Radicheva LV, Amatya C, Parker C, Ellefson J, Wasserfall C, Atkinson M, Burn P, and Savinov AY. Nardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development. Diabetes. 2014 Oct;63(10):3470-82. doi: 10.2337/db14-0213.

Maneva-Radicheva L, Amatya C, Parker C, Ellefson J, Radichev I, Raghavan A, Charles ML, Williams MS, Robbins MS, and Savinov AY. Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1. PLoS One. 2014 Sep 26;9(9):e107213. doi: 10.1371/journal.pone.0107213.

Savinov AY, Rozanov DV, Strongin AY. Specific inhibition of autoimmune T cell transmigration contributes to beta cell functionality and insulin synthesis in non-obese diabetic (NOD) mice. J Biol Chem. 2007 Nov 2;282(44):32106-11.

Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, and Strongin AY. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res. 2006 Mar 1;66(5):2716-24.

Savinov AY, Rozanov DV, Golubkov VS, Wong FS, and Strongin AY. Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. J Biol Chem. 2005 Jul 29;280(30):27755-8.

Savinov AY, Wong FS, Stonebraker AC, and Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med. 2003 Mar 3;197(5):643-56.

Savinov AY, Tcherepanov A, Green EA, Flavell RA, and Chervonsky AV. Contribution of Fas to diabetes development. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):628-32. Epub 2003 Jan 13.

Savinov AY, Wong FS, and Chervonsky AV. IFN-gamma affects homing of diabetogenic T cells. J Immunol. 2001 Dec 1;167(11):6637-43.


Return to Members main page.